Atrial fibrillation and antithrombotic prevention
Atrial fibrillation belongs to the most widespread violations of a rhythm of warm activity and meets in the general population of the population in 1-2% of cases, and with age incidence of this pathology grows. Was the main reason for emergence of atrial fibrillation in the past it is considered to be existence of a mitral stenosis of a rheumatic etiology. In the present time it most often is associated with coronary heart disease, chronic heart failure, and also arterial hypertension. Many decades cardiologists study this violation of a rhythm. On the one hand, it is well-known pathology and rather investigated. On the other hand, the questions connected with the development mechanism, features of a thrombogenesis and antiarrhytmic therapy remain open against constant increase in number of patients with atrial fibrillation, and also emergence of new medicines in the pharmaceutical market. The most discussing among above mentioned groups is antithrombotic prevention at atrial fibrillation as in this area there are new pharmacological preparations demanding the deep analysis.